{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:32:01Z","timestamp":1778772721497,"version":"3.51.4"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Pulmonary hypertension (PH) due to systolic left ventricular dysfunction (PH-sLVD) frequently complicates heart failure (HF), and greatly worsens the prognosis of patients with sLVD, but as yet has no approved treatment. The LEPHT study aims to characterize the haemodynamic profile, safety, tolerability, and pharmacokinetic profile of riociguat (BAY 63-2521), an oral stimulator of soluble guanylate cyclase, in patients with PH-sLVD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This 16-week, phase IIb, randomized, placebo-controlled, double-blind study enrols patients with PH-sLVD, defined as left ventricular ejection fraction (LVEF) \u226440% and mean pulmonary arterial pressure (PAPmean) \u226525 mmHg at rest. Patients using optimized HF medication will receive placebo or riociguat 0.5 mg, 1 mg, or up to 2 mg three times daily. The dose will be titrated for 8 weeks, based on systolic blood pressure and well-being, followed by 8 weeks of treatment at a stable dose. The primary efficacy variable is PAPmean, while secondary efficacy endpoints include LVEF, exercise capacity, quality of life, and other haemodynamic and echocardiographic measurements. Safety and pharmacokinetics will also be assessed. After the 16-week study, patients will have the opportunity to be treated with riociguat in a long-term extension phase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The LEPHT study will provide valuable information on the haemodynamic, echocardiographic, and preliminary clinical effects of riociguat in patients with PH-sLVD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT01065454<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjhf\/hfs071","type":"journal-article","created":{"date-parts":[[2012,6,23]],"date-time":"2012-06-23T03:27:09Z","timestamp":1340422029000},"page":"946-953","source":"Crossref","is-referenced-by-count":28,"title":["Left Ventricular Systolic Dysfunction Associated with Pulmonary Hypertension Riociguat Trial (LEPHT): Rationale and Design"],"prefix":"10.1093","volume":"14","author":[{"given":"Stefano","family":"Ghio","sequence":"first","affiliation":[{"name":"Department of Cardiology, Fondazione IRCCS Policlinico San Matteo, University Hospital , Pavia ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Bonderman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Medical University of Vienna \u00a0","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan B.","family":"Felix","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Internal Medicine B, University Medicine, Ernst-Moritz-Arndt-University of Greifswald \u00a0","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein A.","family":"Ghofrani","sequence":"additional","affiliation":[{"name":"University Hospital Giessen and Marburg GmbH, Justus-Liebig University Giessen \u00a0","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos D.","family":"Michelakis","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alberta , Edmonton ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veselin","family":"Mitrovic","sequence":"additional","affiliation":[{"name":"Kerckhoff-Klinik Forschungsgesellschaft mbH , Bad Nauheim ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald J.","family":"Oudiz","sequence":"additional","affiliation":[{"name":"Harbor-UCLA Medical Center , Torrance, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiner","family":"Frey","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Bayer Pharma AG Berlin \u00a0","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lothar","family":"Roessig","sequence":"additional","affiliation":[{"name":"Global Clinical Development, Bayer Pharma AG Berlin \u00a0","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc J.","family":"Semigran","sequence":"additional","affiliation":[{"name":"Cardiology Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,2,18]]},"reference":[{"key":"2026011921173510800_ejhfhfs071-bib-0001","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/j.jacc.2009.04.008","article-title":"Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension","volume":"54","author":"Hoeper","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026011921173510800_ejhfhfs071-bib-0002","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","article-title":"Updated clinical classification of pulmonary hypertension","volume":"54","author":"Simonneau","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026011921173510800_ejhfhfs071-bib-0003","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0735-1097(00)01102-5","article-title":"Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure","volume":"37","author":"Ghio","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"2026011921173510800_ejhfhfs071-bib-0004","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nrcardio.2010.144","article-title":"Pulmonary hypertension with left-sided heart disease","volume":"7","author":"Guazzi","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"2026011921173510800_ejhfhfs071-bib-0005","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.pcad.2011.06.003","article-title":"Pulmonary hypertension associated with left heart disease: characteristics, emerging concepts, and treatment strategies","volume":"54","author":"Haddad","year":"2011","journal-title":"Prog Cardiovasc Dis"},{"key":"2026011921173510800_ejhfhfs071-bib-0006","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.ahj.2009.02.022","article-title":"Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: analysis of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) database","volume":"157","author":"Khush","year":"2009","journal-title":"Am Heart J"},{"key":"2026011921173510800_ejhfhfs071-bib-0007","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0735-1097(99)00408-8","article-title":"Pulmonary hypertension and exercise intolerance in patients with heart failure","volume":"34","author":"Butler","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"2026011921173510800_ejhfhfs071-bib-0008","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1161\/01.CIR.0000013771.30198.82","article-title":"Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk","volume":"105","author":"Cappola","year":"2002","journal-title":"Circulation"},{"key":"2026011921173510800_ejhfhfs071-bib-0009","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.healun.2006.06.015","article-title":"Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure","volume":"25","author":"Grigioni","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"2026011921173510800_ejhfhfs071-bib-0010","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.amjcard.2006.11.052","article-title":"Prognostic importance of pulmonary hypertension in patients with heart failure","volume":"99","author":"Kjaergaard","year":"2007","journal-title":"Am J Cardiol"},{"key":"2026011921173510800_ejhfhfs071-bib-0011","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1161\/CIRCHEARTFAILURE.111.963785","article-title":"What is the prognostic significance of pulmonary hypertension in heart failure?","volume":"4","author":"Chatterjee","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2026011921173510800_ejhfhfs071-bib-0012","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)","volume":"30","author":"Gali\u00e8","year":"2009","journal-title":"Eur Heart J"},{"key":"2026011921173510800_ejhfhfs071-bib-0013","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2010","journal-title":"Circulation"},{"key":"2026011921173510800_ejhfhfs071-bib-0014","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1183\/09031936.00182909","article-title":"Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study","volume":"36","author":"Ghofrani","year":"2010","journal-title":"Eur Respir J"},{"key":"2026011921173510800_ejhfhfs071-bib-0015","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1183\/09031936.00039808","article-title":"First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension","volume":"33","author":"Grimminger","year":"2009","journal-title":"Eur Respir J"},{"key":"2026011921173510800_ejhfhfs071-bib-0016","doi-asserted-by":"crossref","first-page":"P51","DOI":"10.1186\/1471-2210-9-S1-P51","article-title":"Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator in patients with biventricular heart failure","volume":"9","author":"Mitrovic","year":"2009","journal-title":"BMC Pharmacol"},{"key":"2026011921173510800_ejhfhfs071-bib-0017","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ejheart.2008.08.005","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)","volume":"10","author":"Dickstein","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026011921173510800_ejhfhfs071-bib-0018","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1161\/CIRCULATIONAHA.109.192064","article-title":"2009 focused update: ACCF\/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation","volume":"119","author":"Jessup","year":"2009","journal-title":"Circulation"},{"key":"2026011921173510800_ejhfhfs071-bib-0019","first-page":"1691","article-title":"New aspects of guidelines for treatment of chronic heart failure (JCS 2010)","volume":"69","author":"Yokota","year":"2011","journal-title":"Nihon Rinsho"},{"key":"2026011921173510800_ejhfhfs071-bib-0020","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0002-8703(97)70105-4","article-title":"A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST)","volume":"134","author":"Califf","year":"1997","journal-title":"Am Heart J"},{"key":"2026011921173510800_ejhfhfs071-bib-0021","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(96)10488-8","article-title":"Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators","volume":"349","author":"Hampton","year":"1997","journal-title":"Lancet"},{"key":"2026011921173510800_ejhfhfs071-bib-0022","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group","volume":"325","author":"Packer","year":"1991","journal-title":"N Engl J Med"},{"key":"2026011921173510800_ejhfhfs071-bib-0023","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ijcard.2009.03.041","article-title":"Ventilatory efficiency and dyspnea on exertion improvements are related to reduced pulmonary pressure in heart failure patients receiving Sildenafil","volume":"144","author":"Guazzi","year":"2010","journal-title":"Int J Cardiol"},{"key":"2026011921173510800_ejhfhfs071-bib-0024","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/0735-1097(92)90271-N","article-title":"Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure","volume":"19","author":"Katz","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"2026011921173510800_ejhfhfs071-bib-0025","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0735-1097(98)00209-5","article-title":"Coronary endothelial dysfunction in patients with acute-onset idiopathic dilated cardiomyopathy","volume":"32","author":"Mathier","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"2026011921173510800_ejhfhfs071-bib-0026","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1161\/01.CIR.102.14.1718","article-title":"Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management","volume":"102","author":"Moraes","year":"2000","journal-title":"Circulation"},{"key":"2026011921173510800_ejhfhfs071-bib-0027","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jacc.2005.04.060","article-title":"Flow-mediated vasodilation predicts outcome in patients with chronic heart failure: comparison with B-type natriuretic peptide","volume":"46","author":"Meyer","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026011921173510800_ejhfhfs071-bib-0028","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"},{"key":"2026011921173510800_ejhfhfs071-bib-0029","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/01.RES.0000184694.03262.6d","article-title":"Explaining the phenomenon of nitrate tolerance","volume":"97","author":"Munzel","year":"2005","journal-title":"Circ Res"},{"key":"2026011921173510800_ejhfhfs071-bib-0030","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35065611","article-title":"NO-independent regulatory site on soluble guanylate cyclase","volume":"410","author":"Stasch","year":"2001","journal-title":"Nature"},{"key":"2026011921173510800_ejhfhfs071-bib-0031","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1161\/01.CIR.0000055737.15443.F8","article-title":"Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure","volume":"107","author":"Boerrigter","year":"2003","journal-title":"Circulation"},{"key":"2026011921173510800_ejhfhfs071-bib-0032","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1097\/HJH.0b013e32833b558c","article-title":"Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models","volume":"28","author":"Sharkovska","year":"2010","journal-title":"J Hypertens"},{"key":"2026011921173510800_ejhfhfs071-bib-0033","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/CIRCHEARTFAILURE.110.959437","article-title":"Pulmonary vascular response patterns during exercise in left ventricular systolic dysfunction predict exercise capacity and outcomes","volume":"4","author":"Lewis","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2026011921173510800_ejhfhfs071-bib-0034","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/CIRCHEARTFAILURE.109.923300","article-title":"Chronic ambulatory intracardiac pressures and future heart failure events","volume":"3","author":"Stevenson","year":"2010","journal-title":"Circ Heart Fail"},{"key":"2026011921173510800_ejhfhfs071-bib-0035","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0140-6736(11)60101-3","article-title":"Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial","volume":"377","author":"Abraham","year":"2011","journal-title":"Lancet"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfs071","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/14\/8\/946\/66442565\/eurjhf_14_8_946.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/14\/8\/946\/66442565\/eurjhf_14_8_946.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:23:03Z","timestamp":1768875783000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/14\/8\/946\/8428935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,1]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2014,2,18]]},"published-print":{"date-parts":[[2012,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjhf\/hfs071","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,8]]},"published":{"date-parts":[[2012,8,1]]}}}